Hims & Hers stock poised for heavy losses after quick U-turn on plan for oral Wegovy competitor

Hims & Hers stock tumbled in early action on Monday after the U.S. company quickly reversed…

Novo Nordisk stock climbs out of hole on FDA chief’s threat to block Hims and Hers pill

Novo Nordisk shares rallied on Friday in what’s still been a painful week as the Food…

Lilly says Mounjaro and Zepbound sales more than doubled as stock rallies

Late last year, Lilly was the first pharmaceutical stock to reach a $1 trillion valuation.

Novo Nordisk CEO tells investors to expect weight-loss drug pricing to go down before it comes back up

Recently-appointed CEO Mike Doustdar has repeatedly reset expectations since his arrival. Pricing and regulatory pressure is…

It’s a hit: Prescriptions for Wegovy weight-loss drug pill surge

The oral weight-loss drug introduced by Novo Nordisk this year in the U.S. is quickly being…

Rising prices and weight-loss drugs are changing the way we eat — and food companies are racing to keep up

A shaky economy, wider adoption of weight-loss drugs, and changing tastes seem to conspire against some…

A new generation of weight-loss drugs is getting closer to patients. Here’s how they differ from Wegovy and Zepbound.

Published: Dec. 18, 2025 at 9:28 a.m. ET Eli Lilly and Novo Nordisk — the dominant players…

This biotech is halting its work with Novo Nordisk and laying off more people

Korro is the latest to rethink its ties with the Danish pharma company.

Trump rolls out pricing deal with weight-loss-drug giants Eli Lilly, Novo Nordisk. Analysts say the pact raises more questions than it answers.

Jessica Hall is a retirement reporter for MarketWatch. She was an Age Boom Academy Fellow with…

Novo Nordisk downgrades sales outlook again amid bidding war with Pfizer for Metsera

Management lowers full-year guidance, warns about competition, launches bid for Metsera.